Elizabeth Hodgkinson

603 total citations
10 papers, 308 citations indexed

About

Elizabeth Hodgkinson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Elizabeth Hodgkinson has authored 10 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Elizabeth Hodgkinson's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Genomics and Diagnostics (3 papers) and Clinical practice guidelines implementation (1 paper). Elizabeth Hodgkinson is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Genomics and Diagnostics (3 papers) and Clinical practice guidelines implementation (1 paper). Elizabeth Hodgkinson collaborates with scholars based in United Kingdom, Australia and Belgium. Elizabeth Hodgkinson's co-authors include Robert E. Coleman, Helen Neville-Webbe, Richard Kaplan, Simon Gollins, Richard H. Wilson, Sarah Kenny, Angela Meade, Michel Seymour, David Propper and Harpreet Wasan and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Elizabeth Hodgkinson

10 papers receiving 299 citations

Peers

Countries citing papers authored by Elizabeth Hodgkinson

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Hodgkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Hodgkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Hodgkinson more than expected).

Fields of papers citing papers by Elizabeth Hodgkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Hodgkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Hodgkinson. The network helps show where Elizabeth Hodgkinson may publish in the future.

Co-authorship network of co-authors of Elizabeth Hodgkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Hodgkinson. A scholar is included among the top collaborators of Elizabeth Hodgkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Hodgkinson. Elizabeth Hodgkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716 2020 ·Lung Cancer ·Sarah Danson, Joe Conner, John Edwards, (unknown), P.M. Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick F. Joyce, (unknown), Kathleen Simpson, Alexander Graham, (unknown), Penella J. Woll	39
2	Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL 2019 ·Annals of Oncology ·Tim Eisen, Eleni Frangou, Ben Smith, (unknown), Richard Kaplan, Bhavna Oza, Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Axel Bex, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Elizabeth Hodgkinson, (unknown), Mahesh Parmar, (unknown)	14
3	P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC 2017 ·Journal of Thoracic Oncology ·Penella J. Woll, Piers Gaunt, Nicola Steele, Samreen Ahmed, C Mulatero, Riyaz Shah, Sarah Danson, Elizabeth Hodgkinson, (unknown), (unknown), (unknown), Lucinda Billingham	17
4	Optimisation of pharmacy content in clinical cancer research protocols: Experience of the United Kingdom Chemotherapy and Pharmacy Advisory Service 2015 ·Clinical Trials ·Philip R. Debruyne, Philip J. Johnson, Lies Pottel, (unknown), Rachel Greer, Elizabeth Hodgkinson, Stephen Kelly, Michelle Lycke, Jens Samol, (unknown), (unknown), (unknown), Mahesh Parmar, Sally A. Harvey	2
5	FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC). 2012 ·Journal of Clinical Oncology ·Tim Maughan, Richard H. Wilson, Geraint T. Williams, Michel Seymour, Susan D. Richman, Philip Quirke, Janet Pope, (unknown), Mahesh Parmar, Annmarie Nelson, Angela Meade, Laura Nichols, Bharat Jasani, Elizabeth Hodgkinson, David J. Fisher, Rachel Butler, John Bridgewater, Richard Adams, Richard Kaplan	2
6	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial 2011 ·The Lancet Oncology ·Richard Adams, Angela Meade, Michel Seymour, Richard H. Wilson, Ayman Madi, David J. Fisher, Sarah Kenny, (unknown), Elizabeth Hodgkinson, (unknown), P. Rogers, Harpreet Wasan, Stephen Falk, Simon Gollins, Tamas Hickish, E.M. Bessell, David Propper, Megan Kennedy, Richard Kaplan, Tim Maughan	177
7	Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. 2011 ·Journal of Clinical Oncology ·Tim Maughan, Richard H. Wilson, (unknown), Michel Seymour, Susan D. Richman, Philip Quirke, (unknown), (unknown), (unknown), Anne E. Nelson, Angela Meade, Sarah Kenny, Bharat Jasani, Elizabeth Hodgkinson, David J. Fisher, Rebecca K. Butler, (unknown), Richard Adams, Richard Kaplan	1
8	ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS 2009 ·Annals of Oncology ·(unknown), (unknown), (unknown), Michel Seymour, Robert Wilson, Angela Meade, David I. Fisher, Ayman Madi, Sarah Kenny, Harpreet Wasan, Pauline Rogers, Elizabeth Hodgkinson, Bharat Jasani, Jeremy P. Cheadle, Raphael Kaplan	1
9	Drug Use and Mental Health: Effective Responses to Co‐Occurring Drug and Mental Health Problems 2009 ·Drug and Alcohol Review ·Elizabeth Hodgkinson, (unknown)	9
10	Magnesium Depletion in Patients Receiving Cisplatin-based Chemotherapy 2006 ·Clinical Oncology ·Elizabeth Hodgkinson, Helen Neville-Webbe, Robert E. Coleman	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact